Search

Your search keyword '"Jiang, Gening"' showing total 649 results
Start Over Author "Jiang, Gening" Language english
649 results on '"Jiang, Gening"'

1. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Author

Xia, Haoran, Zhang, Han, Ruan, Zheng, Zhang, Huibiao, Sun, Liangdong, Chen, Hezhong, Zhou, Yongxin, Zhang, Lele, Bian, Dongliang, Zhu, Xinsheng, Zhang, Jing, Sun, Fenghuan, Yu, Huansha, Song, Nan, Liu, Xiaogang, Zhu, Yuming, Zhang, Haiping, He, Wenxin, Chen, Jian, Yang, Jie, Chen, Guohan, Xie, Shiliang, Tang, Dongfang, Zhang, Xiaomiao, Duan, Liang, Zhao, Deping, Li, Qinchuan, Zhang, Peng, and Jiang, Gening

Published
2024
Full Text
View/download PDF

9. Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population

Author

Shi, Jianxin, Shiraishi, Kouya, Choi, Jiyeon, Matsuo, Keitaro, Chen, Tzu-Yu, Dai, Juncheng, Hung, Rayjean J., Chen, Kexin, Shu, Xiao-Ou, Kim, Young Tae, Landi, Maria Teresa, Lin, Dongxin, Zheng, Wei, Yin, Zhihua, Zhou, Baosen, Song, Bao, Wang, Jiucun, Seow, Wei Jie, Song, Lei, Chang, I-Shou, Hu, Wei, Chien, Li-Hsin, Cai, Qiuyin, Hong, Yun-Chul, Kim, Hee Nam, Wu, Yi-Long, Wong, Maria Pik, Richardson, Brian Douglas, Funderburk, Karen M., Li, Shilan, Zhang, Tongwu, Breeze, Charles, Wang, Zhaoming, Blechter, Batel, Bassig, Bryan A., Kim, Jin Hee, Albanes, Demetrius, Wong, Jason Y. Y., Shin, Min-Ho, Chung, Lap Ping, Yang, Yang, An, She-Juan, Zheng, Hong, Yatabe, Yasushi, Zhang, Xu-Chao, Kim, Young-Chul, Caporaso, Neil E., Chang, Jiang, Ho, James Chung Man, Kubo, Michiaki, Daigo, Yataro, Song, Minsun, Momozawa, Yukihide, Kamatani, Yoichiro, Kobayashi, Masashi, Okubo, Kenichi, Honda, Takayuki, Hosgood, Dean H., Kunitoh, Hideo, Patel, Harsh, Watanabe, Shun-ichi, Miyagi, Yohei, Nakayama, Haruhiko, Matsumoto, Shingo, Horinouchi, Hidehito, Tsuboi, Masahiro, Hamamoto, Ryuji, Goto, Koichi, Ohe, Yuichiro, Takahashi, Atsushi, Goto, Akiteru, Minamiya, Yoshihiro, Hara, Megumi, Nishida, Yuichiro, Takeuchi, Kenji, Wakai, Kenji, Matsuda, Koichi, Murakami, Yoshinori, Shimizu, Kimihiro, Suzuki, Hiroyuki, Saito, Motonobu, Ohtaki, Yoichi, Tanaka, Kazumi, Wu, Tangchun, Wei, Fusheng, Dai, Hongji, Machiela, Mitchell J., Su, Jian, Kim, Yeul Hong, Oh, In-Jae, Lee, Victor Ho Fun, Chang, Gee-Chen, Tsai, Ying-Huang, Chen, Kuan-Yu, Huang, Ming-Shyan, Su, Wu-Chou, Chen, Yuh-Min, Seow, Adeline, Park, Jae Yong, Kweon, Sun-Seog, Chen, Kun-Chieh, Gao, Yu-Tang, Qian, Biyun, Wu, Chen, Lu, Daru, Liu, Jianjun, Schwartz, Ann G., Houlston, Richard, Spitz, Margaret R., Gorlov, Ivan P., Wu, Xifeng, Yang, Ping, Lam, Stephen, Tardon, Adonina, Chen, Chu, Bojesen, Stig E., Johansson, Mattias, Risch, Angela, Bickeböller, Heike, Ji, Bu-Tian, Wichmann, H-Erich, Christiani, David C., Rennert, Gadi, Arnold, Susanne, Brennan, Paul, McKay, James, Field, John K., Shete, Sanjay S., Le Marchand, Loic, Liu, Geoffrey, Andrew, Angeline, Kiemeney, Lambertus A., Zienolddiny-Narui, Shan, Grankvist, Kjell, Johansson, Mikael, Cox, Angela, Taylor, Fiona, Yuan, Jian-Min, Lazarus, Philip, Schabath, Matthew B., Aldrich, Melinda C., Jeon, Hyo-Sung, Jiang, Shih Sheng, Sung, Jae Sook, Chen, Chung-Hsing, Hsiao, Chin-Fu, Jung, Yoo Jin, Guo, Huan, Hu, Zhibin, Burdett, Laurie, Yeager, Meredith, Hutchinson, Amy, Hicks, Belynda, Liu, Jia, Zhu, Bin, Berndt, Sonja I., Wu, Wei, Wang, Junwen, Li, Yuqing, Choi, Jin Eun, Park, Kyong Hwa, Sung, Sook Whan, Liu, Li, Kang, Chang Hyun, Wang, Wen-Chang, Xu, Jun, Guan, Peng, Tan, Wen, Yu, Chong-Jen, Yang, Gong, Sihoe, Alan Dart Loon, Chen, Ying, Choi, Yi Young, Kim, Jun Suk, Yoon, Ho-Il, Park, In Kyu, Xu, Ping, He, Qincheng, Wang, Chih-Liang, Hung, Hsiao-Han, Vermeulen, Roel C. H., Cheng, Iona, Wu, Junjie, Lim, Wei-Yen, Tsai, Fang-Yu, Chan, John K. C., Li, Jihua, Chen, Hongyan, Lin, Hsien-Chih, Jin, Li, Liu, Jie, Sawada, Norie, Yamaji, Taiki, Wyatt, Kathleen, Li, Shengchao A., Ma, Hongxia, Zhu, Meng, Wang, Zhehai, Cheng, Sensen, Li, Xuelian, Ren, Yangwu, Chao, Ann, Iwasaki, Motoki, Zhu, Junjie, Jiang, Gening, Fei, Ke, Wu, Guoping, Chen, Chih-Yi, Chen, Chien-Jen, Yang, Pan-Chyr, Yu, Jinming, Stevens, Victoria L., Fraumeni, Jr, Joseph F., Chatterjee, Nilanjan, Gorlova, Olga Y., Hsiung, Chao Agnes, Amos, Christopher I., Shen, Hongbing, Chanock, Stephen J., Rothman, Nathaniel, Kohno, Takashi, and Lan, Qing

Published
2023
Full Text
View/download PDF

12. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies

Author

Liu, Qian, Zhang, Jing, Guo, Chenchen, Wang, Mengcheng, Wang, Chenfei, Yan, Yilv, Sun, Liangdong, Wang, Di, Zhang, Lele, Yu, Huansha, Hou, Likun, Wu, Chunyan, Zhu, Yuming, Jiang, Gening, Zhu, Hongwen, Zhou, Yanting, Fang, Shanhua, Zhang, Tengfei, Hu, Liang, Li, Junqiang, Liu, Yansheng, Zhang, Hui, Zhang, Bing, Ding, Li, Robles, Ana I., Rodriguez, Henry, Gao, Daming, Ji, Hongbin, Zhou, Hu, and Zhang, Peng

Published
2024
Full Text
View/download PDF

19. Prognostic and predictive value of the newly proposed grading system of invasive pulmonary adenocarcinoma in Chinese patients: a retrospective multicohort study

Author

Hou, Likun, Wang, Tingting, Chen, Donglai, She, Yunlang, Deng, Jiajun, Yang, Minglei, Zhang, Yu, Zhao, Mengmeng, Zhong, Yifan, Ma, Minjie, Zhao, Guofang, Chen, Yongbing, Xie, Dong, Zhu, Yuming, Chen, Qiankun, Wu, Chunyan, Chen, Chang, Jiang, Gening, Sun, Xiwen, Jiang, Tao, Jin, Feng, Zhang, Yunzeng, Yu, Bentong, Jiang, Lei, Song, Yongxiang, Chen, Cheng, Qu, Wendong, Zhao, Lilan, and Pan, Xiaojie

Published
2022
Full Text
View/download PDF

22. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Author

Zhu, Xinsheng, Sun, Liangdong, Song, Nan, He, Wenxin, Xie, Boxiong, Hu, Junjie, Zhang, Jing, Yang, Jie, Dai, Jie, Bian, Dongliang, Xia, Haoran, Sun, Fenghuan, Xiong, Anwen, Luo, Jie, Zhang, Lele, Yu, Huansha, Liu, Ming, Liu, Hongcheng, Wang, Haifeng, Zhang, Haiping, Chen, Chang, Wu, Chunyan, Duan, Liang, Zhu, Yuming, Zhang, Peng, and Jiang, Gening

Published
2022
Full Text
View/download PDF

30. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single‐cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.

Author

Fang, Xinyun, Li, Dianke, Wan, Shiyue, Hu, Junjie, Zhang, Peng, Jie, Dai, Chen, Linsong, Jiang, Gening, and Song, Nan

Abstract

Background: Immune checkpoint blockade has emerged as a key strategy to the therapy landscape of non‐small cell lung cancer (NSCLC). However, notable differences in immunotherapeutic outcomes exist between the two primary NSCLC subtypes: lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). This disparity may stem from the tumor immune microenvironment's heterogeneity at the transcriptome level. Methods: By integrative analysis of transcriptomic characterization of 38 NSCLC patients by single‐cell RNA sequencing, the present study revealed a distinct tumor microenvironment (TME) between LUAD and LUSC, with relevant results further confirmed in bulk transcriptomic and multiplex immunofluorescence (mIF) validation cohort of neoadjuvant immunotherapy patients. Results: LUAD exhibited a more active immune microenvironment compared to LUSC. This included highly expression of HLA I/II in cancer cells, reinforced antigen presentation potential of dendritic cells and enhanced cytotoxic activity observed in T/NK cells. In LUSC, cancer cells highly expressed genes belonging to the aldo‐keto reductases, glutathione S‐transferases and aldehyde dehydrogenase family, negatively correlating with immunotherapy outcomes in the validation cohort of our center. Further analysis revealed elevated infiltrated cancer‐associated fibroblasts (CAFs) in LUSC, which was corroborated in The Cancer Genome Atlas cohort. Corresponding increased infiltration of ADH1B+ CAFs in major pathologic response (MPR) patients and the higher presence of FAP+ CAFs in non‐MPR patients were demonstrated by multiplex mIF. Moreover, upregulating immunosuppressive extracellular matrix remodeling was identified in LUSC. Conclusions: These comprehensive analyses advance the understanding of the differences in TME between LUAD and LUSC, offering insights for patient selection and developing subtype‐specific treatment strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. MAIT cells are associated with responsiveness to neoadjuvant immunotherapy in COPD‐associated NSCLC.

Author

Yin, Yanze, Zeng, Ao, Abuduwayiti, Abudumijiti, Xu, Zhilong, Chen, Keyi, Wang, Chao, Fang, Xinyun, Wang, Jiarui, Jiang, Gening, and Dai, Jie

Subjects
CHRONIC obstructive pulmonary disease, NON-small-cell lung carcinoma, IMMUNOTHERAPY, BIOMARKERS
Abstract

Background: Patients with non‐small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) experience worse clinical outcomes but respond better to immunotherapy than patients with NSCLC without COPD. Mucosal‐associated invariant T (MAIT) cells, a versatile population of innate immune T lymphocytes, have a crucial function in the response to infection and tumors. This study investigated the distribution of MAIT cells in COPD‐associated NSCLC and their involvement in the immune response. Methods: Flow cytometry, immunohistochemistry, and immunofluorescence were performed on tissue samples of patients with NSCLC, with or without COPD, treated with or without anti‐programmed death 1 (PD1) immunotherapy. MAIT cells were stimulated with 5‐OP‐RU using a mouse subcutaneous tumor model. Results: Tumors contained significantly more MAIT cells than paraneoplastic tissues, and CD8+ MAIT cells accounted for more than 90% of these cells. Patients with NSCLC and COPD had higher CD8+ MAIT cell counts than those with NSCLC without COPD. Additionally, patients with NSCLC and COPD displayed reduced expression of the activation marker, CD69, and functional markers, granzyme B (GZMB) and interferon γ (IFNγ), and higher expression of the immune exhaustion marker, PD1. Among patients who received immunotherapy, the proportion with a complete or partial response was higher in those with COPD than in those without COPD. In patients with NSCLC and COPD, the major pathologic response (MPR) group had higher MAIT levels than those in the no major pathologic response (NPR) group. In the mouse subcutaneous tumor model stimulation of MAIT cells using 5‐OP‐RU enhanced the antitumor effects of anti‐PD1. Conclusions: In patients with NSCLC and COPD, response to immunotherapy is associated with accumulation of CD8+ MAIT cells showing immune exhaustion. These findings may contribute to innovative approaches for immunotherapy targeting CD8+ MAIT cells. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Surgical strategies for benign acquired tracheoesophageal fistula.

Author

Zeng, Ao, Liu, Xiaogang, Shaik, Mohammed Saud, Jiang, Gening, and Dai, Jie

Subjects
TRACHEAL fistula, ARTIFICIAL respiration, BIOABSORBABLE implants, LUNG infections, TEFF, ENGLISH literature, OPERATIVE surgery
Abstract

Open in new tab Download slide OBJECTIVES Tracheoesophageal fistula (TEF) is characterized by abnormal connectivity between the posterior wall of the trachea or bronchus and the adjacent anterior wall of the oesophagus. Benign TEF can result in serious complications; however, there is currently no uniform standard to determine the appropriate surgical approach for repairing TEF. METHODS The PubMed database was used to search English literature associated with TEF from 1975 to October 2023. We employed Boolean operators and relevant keywords: 'tracheoesophageal fistula', 'tracheal resection', 'fistula suture', 'fistula repair', 'fistula closure', 'flap', 'patch', 'bioabsorbable material', 'bioprosthetic material', 'acellular dermal matrix', 'AlloDerm', 'double patch', 'oesophageal exclusion', 'oesophageal diversion' to search literature. The evidence level of the literature was assessed based on the GRADE classification. RESULTS Nutritional support, no severe pulmonary infection and weaning from mechanical ventilation were the 3 determinants for timing of operation. TEFs were classified into 3 levels: small TEF (<1 cm), moderate TEF (≥1 but <5 cm) and large TEF (≥5 cm). Fistula repair or tracheal segmental resection was used for the small TEF with normal tracheal status. If the anastomosis cannot be finished directly after tracheal segmental resection, special types of tracheal resection, such as slide tracheoplasty, oblique resection and reconstruction, and autologous tissue flaps were preferred depending upon the site and size of the fistula. Oesophageal exclusion was applicable to refractory TEF or patients with poor conditions. CONCLUSIONS The review primarily summarizes the main surgical techniques employed to repair various acquired TEF, to provide references that may contribute to the treatment of TEF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results